A Phase 2 interventional study of Ranibizumab in Macular Degeneration, sponsored by Genentech, Inc.. Completed at 50 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-05-06.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 31st largest by enrollment of the 124 interventional ones that give a count, is one of 7 that started in 2015, is one of 24 in phase 2, and was the 101st registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 2, and was the 13th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This is a Phase II multicenter, dose-ranging, randomized, active treatment (monthly ITV injection)-controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three ranibizumab formulation arms (10 mg/mL, 40 mg/mL, and 100 mg/mL) compared with the control arm (0.5-mg monthly ITV injections of 10-mg/mL formulation) in participants with subfoveal neovascular age-related macular degeneration (nAMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
Drug: Ranibizumab
Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
Drug: Ranibizumab
Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
Drug: Ranibizumab
Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
Drug: Ranibizumab
Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations.
Also known as: Lucentis®
Time Until a Participant First Requires the Implant Refill According to Protocol-Defined Refill Criteria
Protocol-Defined Refill Criteria At 1 month after initial fill: * Decrease of ≥ 10 letters in BCVA at the current visit compared with the baseline BCVA, due to nAMD disease activity OR * Increase in CFT of ≥ 100 um at the current visit compared with the baseline CFT, due to nAMD disease activity OR * Presence of new macular hemorrhage, due to nAMD disease activity For subsequent assessments: * Increase in CFT of ≥ 75 μm on SD-OCT at the current visit compared with the average CFT over the last 2 available measurements, due to nAMD disease activity OR * Increase in CFT of ≥ 100 um from the lowest CFT measurement on study, due to nAMD disease activity OR * Decrease of ≥ 5 letters in BCVA at the current visit compared with the average BCVA over the last 2 available measurements, due to nAMD disease activity OR * Decrease of ≥ 10 letters from best recorded BCVA on study, due to nAMD disease activity OR * Presence of new macular hemorrhage, due to nAMD disease activity
Time frame: Baseline up to approximately 38 months
Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged At Month 9 and 10
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.
Time frame: Baseline, Months 9, 10
Change From Baseline in BCVA Over Time
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.
Time frame: Baseline up to Month 10
Adjusted Average Change From Baseline in BCVA Over Time (MMRM Analysis)
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning. Here, the adjusted mean from MMRM analysis is presented).
Time frame: Baseline up to Month 10
Change From Baseline in Central Foveal Thickness (CFT) Over Time as Assessed on Spectral Domain-Optical Coherence Tomography (SD-OCT)
Central foveal thickness (CFT) is defined as the retinal thickness in the center of the fovea
Time frame: Baseline up to Month 9
Number of Implant Clogging at Month 9
Removed implants identified as meeting serum PK criteria for possible clogging were assessed via lab-based investigation (in vitro drug release testing) to determine whether there was any implant clogging.
Time frame: Month 9
Observed Maximum Serum Concentration (Cmax) of Ranibizumab
The serum pharmacokinetics of ranibizumab were characterized by estimating Cmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
Time frame: Predose (0 hour) on Day 1 up to 38 months
Area Under the Concentration-Time Curve From Dosing to Last Observation (AUClast) of Ranibizumab
AUCLast is defined as area under the concentration-time curve from dosing (implant or refill) to last observation before next refill or exiting the study. The serum pharmacokinetics of ranibizumab were characterized by estimating AUC between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
Time frame: Predose (0 hour) on Day 1 up to approximately 38 months (detailed timeframe is provided in description field)
Time to Maximum Concentration (Tmax) of Ranibizumab
The serum pharmacokinetics of ranibizumab were characterized by estimating Tmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
Time frame: Predose (0 hour) on Day 1 up to 38 months
Terminal Half-Life (t1/2) of Ranibizumab
The serum pharmacokinetics of ranibizumab were characterized by estimating t1/2 between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
Time frame: Predose (0 hour) on Day 1 up to 38 months
Observed Steady-State Serum Concentration at the End of a Dosing Interval (Ctrough) of Ranibizumab
Time frame: Predose (0 hour) on Day 1 up to 38 months
Number of Participants With Ocular and Non-Ocular Adverse Events (AEs) and Serious AEs (SAEs)
Time frame: Baseline up to approximately Month 38
Percentage of Participants With Positive Serum Antibodies to Ranibizumab
Time frame: Baseline up to 38 months
Participants with subfoveal neovascularization secondary to AMD diagnosed within 9 months and treated with ITV anti-VEGF agents were enrolled in the study. Written informed consent was obtained before initiation of any study-related procedures. A participant's screening occurred no sooner than 7 days following administration of the last ITV ranibizumab treatment to the study eye. The screening visit was followed by the randomization visit.
| Milestone | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Started | 59 | 62 | 63 | 41 |
| Completed | 51 | 56 | 56 | 36 |
| Not completed | 8 | 6 | 7 | 5 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 2 | 1 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 | 1 | 0 |
| Withdrew: Participant moved out of the area | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 3 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 4 | 3 |
Protocol-Defined Refill Criteria At 1 month after initial fill: * Decrease of ≥ 10 letters in BCVA at the current visit compared with the baseline BCVA, due to nAMD disease activity OR * Increase in CFT of ≥ 100 um at the current visit compared with the baseline CFT, due to nAMD disease activity OR * Presence of new macular hemorrhage, due to nAMD disease activity For subsequent assessments: * Increase in CFT of ≥ 75 μm on SD-OCT at the current visit compared with the average CFT over the last 2 available measurements, due to nAMD disease activity OR * Increase in CFT of ≥ 100 um from the lowest CFT measurement on study, due to nAMD disease activity OR * Decrease of ≥ 5 letters in BCVA at the current visit compared with the average BCVA over the last 2 available measurements, due to nAMD disease activity OR * Decrease of ≥ 10 letters from best recorded BCVA on study, due to nAMD disease activity OR * Presence of new macular hemorrhage, due to nAMD disease activity
| Months | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL |
|---|---|---|---|
| Time Until a Participant First Requires the Implant Refill According to Protocol-Defined Refill Criteria | 8.7 (6.93 to 9.00) | 13.0 (11.76 to 24.61) | 15.8 (12.06 to 20.63) |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.
| Units on scale | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged At Month 9 and 10 | -3.3 (-5.6 to -1.0) | -0.3 (-2.5 to 1.8) | 5.0 (2.8 to 7.2) | 3.2 (0.6 to 5.8) |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning.
| Units on scale | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Month 1 | -6.6 (-11.0 to -2.3) | -4.7 (-8.8 to -0.6) | -4.9 (-9.1 to -0.6) | 2.4 (-2.6 to 7.5) |
| Month 2 | -2.4 (-4.3 to -0.6) | -1.4 (-3.2 to 0.4) | 1.6 (-0.2 to 3.5) | 2.0 (-0.2 to 4.2) |
| Month 3 | -0.7 (-2.4 to 1.0) | -0.6 (-2.2 to 1.0) | 2.4 (0.8 to 4.1) | 2.7 (0.7 to 4.7) |
| Month 4 | -1.4 (-3.4 to 0.7) | -1.1 (-3.0 to 0.8) | 3.1 (1.1 to 5.1) | 1.9 (-0.4 to 4.3) |
| Month 5 | -1.3 (-3.4 to 0.8) | -0.6 (-2.5 to 1.4) | 3.8 (1.8 to 5.8) | 3.0 (0.6 to 5.3) |
| Month 6 | -0.4 (-3.0 to 2.3) | -1.7 (-4.3 to 0.8) | 3.8 (1.2 to 6.4) | 2.7 (-0.4 to 5.7) |
| Month 7 | -0.9 (-3.2 to 1.4) | -1.8 (-4.0 to 0.3) | 3.9 (1.7 to 6.1) | 3.5 (0.9 to 6.1) |
| Month 8 | -2.4 (-4.7 to -0.1) | -1.2 (-3.3 to 1.0) | 4.0 (1.8 to 6.2) | 3.3 (0.7 to 5.9) |
| Month 9 | -3.3 (-5.7 to -0.9) | -0.5 (-2.7 to 1.7) | 5.0 (2.7 to 7.3) | 3.9 (1.1 to 6.6) |
| Month 10 | -3.3 (-5.7 to -1.0) | -0.2 (-2.4 to 2.0) | 5.1 (2.8 to 7.3) | 2.5 (-0.2 to 5.2) |
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. The minimum score possible is 0 and maximum possible is 100. A higher score represents better functioning. Here, the adjusted mean from MMRM analysis is presented).
| Units on scale | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Adjusted Average Change From Baseline in BCVA Over Time (MMRM Analysis) | -7.5 ± 74.0 | -8.5 ± 59.1 | 29.7 ± 54.7 | 21.3 ± 65.1 |
Central foveal thickness (CFT) is defined as the retinal thickness in the center of the fovea
| microns | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Month 1 | 16.5 (4.1 to 29.0) | 7.2 (-4.5 to 18.9) | -2.9 (-15.1 to 9.2) | 2.5 (-11.7 to 16.7) |
| Month 2 | 19.8 (6.9 to 32.7) | 11.9 (-0.3 to 24.1) | -1.8 (-14.5 to 10.9) | 1.5 (-13.3 to 16.4) |
| Month 3 | 24.9 (11.5 to 38.3) | 7.3 (-5.5 to 20.0) | 6.4 (-6.8 to 19.6) | -7.3 (-22.9 to 8.3) |
| Month 4 | 31.0 (15.8 to 46.1) | 4.1 (-10.3 to 18.5) | 1.9 (-13.2 to 16.9) | -1.7 (-19.2 to 15.9) |
| Month 5 | 30.9 (16.1 to 45.7) | 0.4 (-13.6 to 14.5) | 8.0 (-6.7 to 22.9) | 4.0 (-13.0 to 21.1) |
| Month 6 | 31.9 (15.6 to 48.1) | 2.1 (-13.1 to 17.3) | 5.9 (-10.0 to 21.7) | -2.0 (-20.4 to 16.4) |
| Month 7 | 39.9 (25.6 to 54.3) | 0.7 (-12.5 to 14.0) | -4.3 (-18.3 to 9.6) | -9.8 (-25.9 to 6.3) |
| Month 8 | 42.8 (26.4 to 59.1) | 3.1 (-12.1 to 18.3) | 5.1 (-10.6 to 20.8) | -2.4 (-20.8 to 16.1) |
| Month 9 | 54.8 (37.1 to 72.4) | -0.7 (-16.9 to 15.5) | -1.7 (-18.5 to 15.1) | -6.3 (-26.1 to 13.4) |
Removed implants identified as meeting serum PK criteria for possible clogging were assessed via lab-based investigation (in vitro drug release testing) to determine whether there was any implant clogging.
| Participants | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL |
|---|---|---|---|
| Number of Implant Clogging at Month 9 | 0 | 0 | 0 |
The serum pharmacokinetics of ranibizumab were characterized by estimating Cmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
| pg/mL | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Interval following implant insertion before first refill | 105.52 ± 258.0 | 220.87 ± 46.4 | 1080.69 ± 272.5 | — |
| All Dose Intervals | 91.47 ± 187.2 | 297.61 ± 115.2 | 1131.01 ± 256.6 | — |
AUCLast is defined as area under the concentration-time curve from dosing (implant or refill) to last observation before next refill or exiting the study. The serum pharmacokinetics of ranibizumab were characterized by estimating AUC between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
| ng∙day/mL | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Interval following implant insertion before first refill | 5.89 ± 225.1 | 28.39 ± 107.6 | 90.83 ± 64.7 | — |
| All Dose Intervals | 3.43 ± 176.8 | 22.93 ± 96.9 | 66.12 ± 71.4 | — |
The serum pharmacokinetics of ranibizumab were characterized by estimating Tmax between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
| days | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Interval following implant insertion before first refill | 11.45 (0 to 688.1) | 12.87 (0 to 86.0) | 29.01 (0.8 to 180.3) | — |
| All Dose Intervals | 4.87 (0 to 688.1) | 6.71 (0 to 91.1) | 6.97 (0.8 to 180.3) | — |
The serum pharmacokinetics of ranibizumab were characterized by estimating t1/2 between dose intervals. Estimates for these parameters were tabulated and summarized by descriptive statistics.
| days | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Interval following implant insertion before first refill | 168.20 ± 163.3 | 88.30 ± 46.7 | 119.07 ± 128.4 | — |
| All Dose Intervals | 162.36 ± 129.3 | 118.87 ± 76.2 | 143.87 ± 171.4 | — |
| pg/mL | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| Interval following implant insertion before first refill | 14.96 ± 76.4 | 61.64 ± 95.8 | 129.63 ± 149.2 | — |
| All Dose Intervals | 11.58 ± 65.7 | 105.07 ± 77.4 | 62.19 ± 345.2 | — |
| Participants | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Ranibizumab PD All Participants | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|---|
| Participants with ocular SAEs in study eye | 7 | 6 | 4 | 17 | 0 |
| Participants with ocular AEs in study eye | 56 | 58 | 52 | 166 | 26 |
| Participants with non-ocular SAEs | 8 | 16 | 13 | 37 | 4 |
| Participants with non-ocular AEs | 46 | 52 | 52 | 150 | 36 |
| Percentage of Participants | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Ranibizumab PD All Participants | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|---|
| Participants with a positive sample at time of entry into the study (Baseline) | 10.3 | 5.0 | 5.1 | 6.8 | 0 |
| Participants positive for Treatment Emergent ADA (Post-baseline) | 6.9 | 14.5 | 15.3 | 12.3 | 14.6 |
Collected over Baseline up to approximately Month 38. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Port Delivery System With Ranibizumab 10mg/mL | 1/58 (1.7%) | 14/58 (24.1%) | 57/58 (98.3%) |
| Port Delivery System With Ranibizumab 40mg/mL | 2/62 (3.2%) | 19/62 (30.6%) | 59/62 (95.2%) |
| Port Delivery System With Ranibizumab 100mg/mL | 1/59 (1.7%) | 17/59 (28.8%) | 58/59 (98.3%) |
| Intravitreal Injection With Ranibizumab 0.5mg | 1/41 (2.4%) | 4/41 (9.8%) | 35/41 (85.4%) |
| Event | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 2/58 | 4/62 | 0/59 | 1/41 |
| VITREOUS HAEMORRHAGEEye disorders | 3/58 | 2/62 | 2/59 | 0/41 |
| SEPSISInfections and infestations | 0/58 | 3/62 | 0/59 | 0/41 |
| RHEGMATOGENOUS RETINAL DETACHMENTEye disorders | 2/58 | 1/62 | 2/59 | 0/41 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 2/58 | 0/62 | 0/59 | 0/41 |
| BRONCHITISInfections and infestations | 0/58 | 0/62 | 2/59 | 0/41 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/58 | 2/62 | 0/59 | 0/41 |
| HIATUS HERNIAGastrointestinal disorders | 0/58 | 2/62 | 0/59 | 0/41 |
| INFLUENZAInfections and infestations | 0/58 | 2/62 | 0/59 | 0/41 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 0/58 | 2/62 | 1/59 | 0/41 |
| Event | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg |
|---|---|---|---|---|
| CONJUNCTIVAL HAEMORRHAGEEye disorders | 41/58 | 44/62 | 37/59 | 8/41 |
| CONJUNCTIVAL HYPERAEMIAEye disorders | 18/58 | 13/62 | 14/59 | 0/41 |
| EYE PAINEye disorders | 12/58 | 12/62 | 15/59 | 5/41 |
| VITREOUS FLOATERSEye disorders | 13/58 | 9/62 | 12/59 | 4/41 |
| IRITISEye disorders | 8/58 | 13/62 | 7/59 | 0/41 |
| NASOPHARYNGITISInfections and infestations | 12/58 | 8/62 | 9/59 | 6/41 |
| CATARACTEye disorders | 3/58 | 5/62 | 12/59 | 5/41 |
| HEADACHENervous system disorders | 9/58 | 8/62 | 11/59 | 1/41 |
| VITREOUS DETACHMENTEye disorders | 7/58 | 6/62 | 4/59 | 7/41 |
| SINUSITISInfections and infestations | 2/58 | 5/62 | 9/59 | 7/41 |
| Age, Categorical(Participants) | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 7 | 9 | 7 | 31 |
| >=65 years | 51 | 55 | 54 | 34 | 194 |
| Age, Continuous(Years) | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg | Total |
|---|---|---|---|---|---|
| Mean | 74.6 ± 8.4 | 75.0 ± 8.5 | 73.8 ± 8.1 | 71.9 ± 8.8 | 74.0 ± 8.4 |
| Sex: Female, Male(Participants) | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg | Total |
|---|---|---|---|---|---|
| Female | 37 | 39 | 42 | 28 | 146 |
| Male | 22 | 23 | 21 | 13 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 3 | 1 | 10 |
| Not Hispanic or Latino | 56 | 56 | 60 | 39 | 211 |
| Unknown or Not Reported | 0 | 3 | 0 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Port Delivery System With Ranibizumab 10mg/mL | Port Delivery System With Ranibizumab 40mg/mL | Port Delivery System With Ranibizumab 100mg/mL | Intravitreal Injection With Ranibizumab 0.5mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 58 | 61 | 60 | 41 | 220 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Apr 2018, 30 months.
Results were first posted in May 2021, 3 years after primary completion. A results delay was requested in Apr 2019.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab